About
Technology
Issues
FAQ
Links
Official Page
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.